Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
Arcadia: Transforming Healthcare with Data-Driven Solutions
What You Should Know: – Arcadia® (arcadia.io), a leading data platform for healthcare, today announced the launch of two new solutions—Enhanced Benchmarks and Arcadia Vista Push—designed